Transcatheter mitral valve repair device for the treatment of tricuspid or tricuspid and mitral regurgitation a review of clinical effectiveness and cost-effectiveness

The purpose of this report is to summarize the clinical effectiveness and cost-effectiveness of the transcatheter mitral valve repair device for TR with or without mitral regurgitation

Bibliographic Details
Main Authors: Li, Ke Xin, Wright, Mary-Doug (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2020, June 02, 2020
Edition:Version: 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01579nam a2200337 u 4500
001 EB001999899
003 EBX01000000000000001162800
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
100 1 |a Li, Ke Xin 
245 0 0 |a Transcatheter mitral valve repair device for the treatment of tricuspid or tricuspid and mitral regurgitation  |h Elektronische Ressource  |b a review of clinical effectiveness and cost-effectiveness  |c Ke Xin Li, Mary-Doug Wright 
250 |a Version: 1.0 
260 |a Ottawa (ON)  |b CADTH  |c 2020, June 02, 2020 
300 |a 1 PDF file (24 pages)  |b illustrations 
653 |a Canada 
653 |a Heart Valve Prosthesis 
653 |a Cost-Benefit Analysis 
653 |a Tricuspid Valve Insufficiency / surgery 
653 |a Treatment Outcome 
653 |a Mitral Valve Insufficiency / surgery 
653 |a Heart Valve Prosthesis Implantation / instrumentation 
700 1 |a Wright, Mary-Doug  |e [author] 
710 2 |a Canadian Agency for Drugs and Technologies in Health  |b Rapid Response Service 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK564102  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 580 
082 0 |a 700 
520 |a The purpose of this report is to summarize the clinical effectiveness and cost-effectiveness of the transcatheter mitral valve repair device for TR with or without mitral regurgitation